RecruitingMucopolysaccharidosis IH/SMucopolysaccharidosis IS
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
Eligible age
10+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A first-in-human study using ISP-001 in patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
Sponsor: Immusoft of CA, Inc.
You may qualify if…
- ✓ Diagnosis of Mucopolysaccharidosis type I Hurler-Scheie or Scheie syndrome.
- ✓ Age ≥ 10 years at time of study registration.
- ✓ Creatinine clearance, calculated or measured directly, that is \>60ml/min/1.73m2.
- ✓ Ejection fraction ≥ 40% by echocardiogram.
- ✓ Must commit to traveling to the study site for the necessary follow-up evaluations.
- ✓ Must agree to stay \<45-minute drive from the study site for a minimum of 5 days after cell infusion.
You may not qualify if…
- ✕ Known familial inherited cancer syndrome. Suspected cases will be investigated, per the physicians discretion, using relevant genetic tests to determine presence of germline mutations.
- ✕ History of B cell related cancer, EBV lymphoproliferative disease or autoimmune disorders.
- ✕ Evidence of active graft-vs-host disease.
- ✕ Underwent a previous hematopoietic stem cell transplant (HSCT).
- ✕ Requirement for systemic immune suppression.
- ✕ Requirement for continuous supplemental oxygen.
- ✕ Any medical condition likely to interfere with assessment of safety or efficacy of the study treatment.
- ✕ In the investigator's judgement, the subject is unlikely to complete all protocol-required study visits or procedures, including follow up visits, or comply with the study requirements for participation.
Where it's recruiting
California
Oakland
Minnesota
Minneapolis
Source: ClinicalTrials.gov · NCT05682144 · last updated 2026-07-17